Dr. Aseem Malhotra on statins: what the evidence says · JRE #1979

What the evidence says 01 / RECORD

Malhotra's figure reflects a real statistic used in the statin debate: absolute risk reduction (ARR) from statins in primary prevention (people without a prior heart attack or stroke) is genuinely small in percentage-point terms compared with the drug's relative risk reduction, and low-risk individuals see even smaller absolute benefit than higher-risk ones. A 2013 Cochrane systematic review of statins for primary prevention found they reduce cardiovascular events and mortality with a favorable benefit-harm profile, with absolute benefit scaling with baseline risk. A 2016 Lancet analysis led by Oxford's Rory Collins, published specifically to counter exaggerated claims about statin harms and understated claims about benefits, reported that in primary-prevention patients at increased (not high) cardiovascular risk, statin therapy over 5 years prevents major vascular events in about 5% of those treated (roughly 500 per 10,000), a larger absolute benefit than the 1% figure Malhotra cites for genuinely low-risk people; benefit is smaller for the lowest-risk patients and larger for higher-risk ones. The American Heart Association similarly holds that statins reduce cardiovascular events and mortality across risk categories and that benefit accumulates with longer treatment duration, a nuance often omitted when a single-digit absolute-risk-reduction number is presented in isolation. Malhotra's specific 1% figure is not clearly false for some very-low-risk subgroups over shorter timeframes, but presenting it as the general benefit for anyone without a prior heart attack, without noting that risk-based prescribing and longer treatment duration meaningfully change the number, is a form of statistical framing that cardiology researchers have specifically criticized as misleading when used to argue people should decline statins.